secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2022-03-08T23:59:59+00:00
Accession:  0001104659-22-031232
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron extends $720M lease financing for headquarters by five years to 2027
------------------------------------------------------------------------------

- Five-year extension of $720M lease financing originally from 2017; new maturity March 3, 2027.
- Yield on advances changed to one-month SOFR plus spread adjustment and margin tied to debt rating/leverage.
- Lessee may extend another five years with all Participants' consent; prepayment allowed without premium.
- Guarantors: Regeneron, Regeneron Healthcare Solutions, and Regeneron Genetics Center (joint and several).
- Covenants mirror existing credit agreement: max total leverage ratio, min interest expense coverage, restricted payments test.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000110465922031232/0001104659-22-031232-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000110465922031232/tm222431d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-031232

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer